Background: Little is known about the effectiveness and drug survival associated with apremilast under real-world conditions.
Objective: To investigate the influence of patient and disease characteristics on drug survival associated with apremilast and to elucidate clinical effectiveness with regard to the psoriasis area and severity index (PASI) reduction.
Methods: This was an observational, retrospective, multicenter analysis from the Austrian Psoriasis Registry.